Show simple item record

dc.contributor.authorZaman, Mehfuz
dc.contributor.authorAbdel-Aal, Abu-Baker M
dc.contributor.authorFujita, Yoshio
dc.contributor.authorZiora, Zyta M
dc.contributor.authorBatzloff, Michael R
dc.contributor.authorGood, Michael F
dc.contributor.authorToth, Istvan
dc.date.accessioned2017-05-03T12:53:54Z
dc.date.available2017-05-03T12:53:54Z
dc.date.issued2012
dc.date.modified2012-12-21T02:57:37Z
dc.identifier.issn0022-2623
dc.identifier.doi10.1021/jm301074n
dc.identifier.urihttp://hdl.handle.net/10072/48798
dc.description.abstractInfection with group A streptococcus (GAS) can result in a number of diseases, some of which are potentially life-threatening. The oral-nasal mucosa is a primary site of GAS infection, and a mucosally active vaccine candidate could form the basis of an antidisease and transmission-blocking GAS vaccine. In the present study, a peptide from the GAS M protein (J14) representing a B cell epitope was incorporated alongside a universal T cell helper epitope and a Toll-like receptor 2 targeting lipid moiety to form lipopeptide constructs. Through structure activity studies, we identified a vaccine candidate that induces J14-specific mucosal and systemic antibody responses when administered intranasally without additional adjuvants. The systemic antibodies elicited were capable of inhibiting the growth of GAS. In addition, J14-specific mucosal antibodies corresponded with reduced throat colonization after respiratory GAS challenge. These preclinical experiments show that this lipopeptide could form the basis of an optimal needle-free mucosal GAS vaccine.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAmerican Chemical Society
dc.publisher.placeUnited States
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom8515
dc.relation.ispartofpageto8523
dc.relation.ispartofissue19
dc.relation.ispartofjournalJournal of Medicinal Chemistry
dc.relation.ispartofvolume55
dc.rights.retentionY
dc.subject.fieldofresearchMedicinal and biomolecular chemistry
dc.subject.fieldofresearchOrganic chemistry
dc.subject.fieldofresearchBacteriology
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode3404
dc.subject.fieldofresearchcode3405
dc.subject.fieldofresearchcode310701
dc.subject.fieldofresearchcode3214
dc.titleStructure-Activity Relationship for the Development of a Self-Adjuvanting Mucosally Active Lipopeptide Vaccine against Streptococcus pyogenes
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.rights.copyrightSelf-archiving of the author-manuscript version is not yet supported by this journal. Please refer to the journal link for access to the definitive, published version or contact the authors for more information.
gro.date.issued2012
gro.hasfulltextNo Full Text
gro.griffith.authorBatzloff, Michael R.
gro.griffith.authorGood, Michael F.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record